Ocrelizumab

Ocrelizumab is a humanized monoclonal antibody that has been approved by the FDA for the treatment of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). It is administered intravenously on a twice-yearly basis and works by targeting and binding to the CD20 antigen, which is present on certain types of immune cells. By binding to the CD20 antigen, ocrelizumab disrupts the activity of these cells and can slow down the progression of MS. It is also thought to have a preventative effect, reducing the incidence of relapses and disability progression. Ocrelizumab has been shown to be an effective treatment option for those with MS, offering a safe, effective, and long-term solution for controlling the symptoms and effects of the condition.